NCT03590938已完成不适用
Lynparza Tablets 100mg, 150mg CEI, Investigation on Development of Bone Marrow Depression in Patients With Unresectable or Recurrent BRCA Mutated HER2 Negative Breast Cancer Who Have Previously Received Anticancer Chemotherapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 111
- 试验地点
- 1
- 主要终点
- Adverse drug reactions of bone marrow depression
研究概览
简要总结
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
详细描述
To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unresectable or recurrent BRCA mutated HER2 negative breast cancer with prior anticancer chemotherapy
排除标准
- •The patients who are not started on Lymparza for the first time
结局指标
主要结局
Adverse drug reactions of bone marrow depression
时间窗: One year period
Bone marrow depression will be investigated as safety specification topics
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)Breast CancerNCT05677308AstraZeneca61
已完成
不适用
Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL AmyloidosisAmyloidosisNCT02716103Boston Medical Center45
已完成
不适用
Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)Ovarian CancerNCT03505307AstraZeneca846
已完成
不适用
Predictive Value of Bone Turnover Markers During Discontinuation With AlendronateOsteoporosisNCT03051620Aarhus University Hospital142
已完成
不适用
LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)Pancreatic NeoplasmsNCT04889404AstraZeneca130